05:07 AM EDT, 05/06/2025 (MT Newswires) -- Bluebird bio (BLUE), Carlyle (CG), SK Capital Partners and Beacon Parent said late Monday that all required regulatory approvals have been received for the Bluebird bio's acquisition by Carlyle and SK Capital.
The companies said no additional approvals are needed, and the merger is expected to close soon on May 12.
Under the deal, Bluebird bio's shareholders will receive $3 per share in cash upfront and a contingent value right worth up to $6.84 per share, based on future sales milestones, bringing the total potential value to $9.84 per share.